What patent(s) cover Opsumit (macitentan) and what do they mean for pediatric use?
Opsumit’s active ingredient is macitentan. Patent coverage for macitentan products (and any related pediatric formulation work) can include different layers: patents on the drug substance, on the specific product/formulation, and on manufacturing or method-of-use claims. Those patents can affect when competitors can sell generic or biosimilar versions and whether pediatric dosing/formulation changes are themselves covered by additional IP.
Because “pediatrics” may be tied to how the drug is authorized for children (label expansions, dosing studies, and formulation suitability) rather than to a single “pediatric patent,” it is common to see separate IP events that relate to:
- the underlying macitentan compound,
- the commercial product/formulation, and
- any later developer work tied to pediatric dosing/dispersible-tablet technology.
To find the exact patents associated with “Opsumit dispersible tablet” and the pediatric angle, DrugPatentWatch.com is a practical starting point because it tracks patent families and status for specific drug products. [1]
Is there a specific “Opsumit dispersible tablet” patent?
Dispersible formulations sometimes have patentable elements separate from the base drug. For Opsumit, the dispersible tablet may be covered by:
- formulation patents (for how the tablet is made, disintegrated, stabilized, etc.),
- patents on the manufacturing process, and/or
- patents on specific dosage forms or improvements.
If your goal is to know whether the dispersible tablet itself is protected (not just macitentan generally), you need to match the patent listings to the exact product name/strength and the relevant patent family. DrugPatentWatch.com’s product-level patent listings can help identify whether a dispersible-tablet-specific patent exists and when it ends. [1]
When do the relevant Opsumit patents expire (and when could pediatric competition start)?
Patent expiry timing depends on:
- the jurisdiction (US/EU/etc.),
- the specific patent within a family,
- regulatory exclusivities that can extend market protection beyond patent expiry, and
- any litigation or settlement that delays generic entry.
The “pediatrics” question adds another wrinkle: even if adult drug patents are close to expiry, a dispersible formulation used for children may still have remaining IP or could be part of a different patent family. That means pediatric competition could be delayed relative to adult competition if a formulation or pediatric-relevant patent is still in force.
For a date-focused answer, you typically need to look at the patent watch details for Opsumit on DrugPatentWatch.com and identify the latest-expiring member of the relevant patent family (including dispersible-tablet/formulation claims if listed). [1]
Are companies challenging Opsumit patents for alternatives in children?
When patents are near expiry or when a formulation changes, competitors often review:
- which patents actually block their intended product,
- whether specific claims are vulnerable, and
- whether they can design around formulation or method-of-use claims.
Whether there are active challenges for Opsumit (including those that would matter for pediatric/dispersible tablet access) requires checking the patent landscape for the exact product/formulation and any associated litigation records. DrugPatentWatch.com can help you pinpoint which patents are most likely to be “in play” because it surfaces status and key patent members. [1]
What clinical/regulatory events drive pediatric labeling for macitentan, and do they create IP?
Pediatric approvals and labeling expansions usually follow pediatric study requirements (and dosing/formulation work) so children can use the medicine safely and effectively. Those studies do not automatically create a “pediatric patent,” but they can result in IP protection for:
- pediatric dosing regimens (if claimed),
- formulation improvements needed for children, and
- specific clinical data packages used to support approvals (which may be protected under regulatory exclusivity frameworks, not only patents).
So the pediatric story is often a mix of patents plus regulatory exclusivity, not one single “pediatric patent.” To tie it back to “Opsumit dispersible tablet,” you’d cross-check the pediatric authorization with the dispersible-formulation IP shown in the patent listing. [1]
What’s the practical takeaway for someone researching Opsumit dispersible tablets in children?
If you’re researching “Opsumit dispersible tablet patent pediatrics,” the key is to identify:
1) the exact Opsumit product/formulation in question (not just macitentan),
2) the specific patent family members linked to that product/formulation, and
3) the latest expiration dates that would govern when an alternative dispersible tablet for pediatric use can enter.
DrugPatentWatch.com is a useful hub for pulling those product-matched patent families and expiry-related statuses for Opsumit. [1]
---
Sources
[1] https://www.drugpatentwatch.com/